Table 8.
Results of tablet evaluation tests during the period of accelerated stability storage conditions.
|
l-Carnitine base tablets prepared by wet granulation |
Formulation C6 containing l-Carnitine base microcapsules |
|||||||
|---|---|---|---|---|---|---|---|---|
| Zero months | One month | Three months | Six months | Zero months | One month | Three months | Six months | |
| Moisture content (%w/w) | 1.623 ±0.02 |
1.843 ±0.1 |
2.353 ±0.18 |
3.250 ±0.12 |
1.323 ±0.09 |
1.393 ±0.02 |
1.520 ±0.06 |
1.843 ±0.04 |
| Weight uniformity (mg) | 998.80 ±0.14 |
999.50 ±0.35 |
1004.60 ±1.13 |
1012.20 ±0.85 |
1002.00 ±0.71 |
1002.10 ±0.10 |
1003.70 ±0.60 |
1006.00 ±0.40 |
| Tablet hardness (kp) | 20.033 ±0.020 |
18.833 ±0.590 |
16.783 ±0.480 |
13.667 ±0.470 |
20.017 ±0.060 |
19.317 ±0.340 |
18.167 ±0.240 |
17.150 ±0.180 |
| Percentage dissolution (%) | 97.905 ±0.770 |
96.21 ±0.90 |
92.773 ±0.870 |
87.55 ±1.80 |
96.33 ±1.18 |
95.683 ±0.220 |
94.125 ±1.060 |
91.87 ±2.03 |
| Drug assay (%) | 99.33 ±0.94 |
98.20 ±1.60 |
96.24 ±0.81 |
93.21 ±0.85 |
99.32 ±1.01 |
98.57 ±1.11 |
97.07 ±0.4 |
95.07 ±0.66 |
Results represent the average of 3 recorded reading for each test.